DEPARTMENT OF AGRICULTURE, ENVIRONMENT AND RURAL AFFAIRS
(NORTHERN IRELAND)

EXPORT OF BOVINE OOCYTES/EMBRYOS (COLLECTED, PRODUCED, PROCESSED AND STORED AFTER 31/12/2004) TO GREAT BRITAIN

Health Certificate No: .....

EXPORT HEALTH CERTIFICATE

EXPORTING COUNTRY: NORTHERN IRELAND

FOR COMPLETION BY: OFFICIAL VETERINARIAN

PART I:

I.1 Information concerning the donor Animal(s)

Breed	Identification of Donor Animal

I.2 Details concerning the consignment

a) Name of consignor:

b) Address of consignor:

c) Number of oocytes/embryos:

d) Dates of collection/production:

e) Place of loading:

I.3 Place of collection of the consignment:

a) Name and address of approved embryo team:

b) Registration number of embryo team:

c) Embryo team veterinarian:

I.4 Destination of the consignment

a) Name of consignee:

b) Address of consignee:

c) Address of destination:

d) Means of transportation:

e) Number/code-mark of containers:

f) Seal number on shipping flask:

I.5 Health Information

I, the undersigned Official Veterinarian (OV), certify that the *oocytes / *embryos described on this health certificate:

(a) were produced/collected, processed and stored by an approved embryo collection/production team approved and supervised in accordance with Chapter 1 of Annex A to Directive 89/556/EEC.

(b) meet the requirements of Chapter II of Annex A to Directive 89/556/EEC.

(c) come from donor females which meet the requirements of Annex B to Directive 89/556/EEC.

(d) *are in vivo derived embryos which were conceived as a result of artificial insemination with semen meeting the requirements of Directive 88/407/EEC;

or

*are in vivo derived/in vitro collected oocytes;

or

*are in vitro produced/micromanipulated embryos which are conceived as a result of in vitro fertilisation with semen meeting the requirements of Directive 88/407/EEC.

(e) were sent to the place of loading in a sealed flask under conditions complying with Directive 89/556/EEC and bearing the number detailed above.

* Delete as appropriate

OV Stamp
Official Veterinarian

Signed .....

Name (BLOCK CAPITALS):.....

Date .....

Address .....

This certificate is valid for 10 days from the date of certification

NOTES

(a) A separate certificate must be issued for each consignment.
(b) The original of this certificate must accompany the consignment to the place of destination.

DEPARTMENT OF AGRICULTURE, ENVIRONMENT AND RURAL AFFAIRS (NORTHERN IRELAND)

SUPPLEMENTARY EXPORT HEALTH CERTIFICATE FOR THE EXPORT OF BOVINE OOCYTES /EMBRYOS FROM NI TO GB FOR FURTHER PROCESSING IN GB AND RETURN TO NI OR EU

Health Certificate No: ……

EXPORTING COUNTRY: NORTHERN IRELAND

FOR COMPLETION BY: OFFICIAL VETERINARIAN

PART II:

I, the undersigned official veterinarian, hereby certify that:

II.1. The oocytes(1)/ *in vivo* derived embryos(1)/ *in vitro* produced embryos(1)/ micromanipulated embryos(1) described in Part I are intended for artificial reproduction and were obtained from the donor animals which originate from Northern Ireland

(1)*either* [II.1.1. where foot-and-mouth disease was not reported for a period of at least 24 months immediately prior to collection(1)/ production(1) of the oocytes(1)/ embryos(1) and until their date of dispatch;]

(1)*or* [II.1.1. where foot-and-mouth disease was not reported for a period starting on the date(2) …… (*insert date dd/mm/yyyy*) immediately prior to collection of the oocytes(1)/ embryos(1) and until their date of dispatch;]

II.1.2 where infection with rinderpest virus, infection with Rift Valley fever virus, contagious bovine pleuropneumonia and lumpy skin disease were not reported for a period of at least 12 months immediately prior to collection(1)/ production(1) of the oocytes(1)/ embryos(1) and until their date of dispatch;

II.1.3 where no vaccination against foot-and-mouth disease, infection with rinderpest virus, infection with Rift Valley fever virus and contagious bovine pleuropneumonia has been carried out for a period of at least 12 months immediately prior to collection(1)/ production(1) of the oocytes(1)/ embryos(1),and until their date of dispatch , and no vaccinated animals entered into the country, territory or zone during that period.

(1)[II.2. The *in vivo* derived embryos described in Part I have been collected, processed and stored, and dispatched by the embryo collection team(3) which

II.2.1. is approved and listed by the competent authority of the country or territory;

II.2.2. complies with requirements as regards responsibilities, operational procedures, facilities and equipment set out in Part 2 of Annex I to Commission Delegated Regulation (EU) 2020/686.]

(1)[II.2. The oocytes(1)/ *in vitro* produced embryos(1) described in Part I have been collected or produced, processed and stored, and dispatched by the embryo production team(3) which

II.2.1. is approved and listed by the competent authority of the country or territory;

II.2.2. complies with requirements as regards responsibilities, operational procedures, facilities

and equipment set out in Parts 2 and 3 of Annex I to Delegated Regulation (EU) 2020/686.]

II.3 The oocytes(1)/ embryos(1) described in Part I were obtained from the donor animals which originate from establishments

II.3.1. free from infection with *Mycobacterium tuberculosis* complex (*M. bovis, M. caprae* and *M. tuberculosis*), and they have never been kept previously in any establishment of a lower health status;

II.3.2. free from infection with *Brucella abortus, B. melitensis* and *B. suis* and they have never been kept previously in any establishment of a lower health status;

(1)*either* [II.3.3. free from enzootic bovine leukosis and they have never been kept previously in any establishment of a lower health status;]

(1)*or* [II.3.3. not free from enzootic bovine leukosis and the official veterinarian responsible for the establishment of origin has certified that there has been no clinical case of enzootic bovine leukosis during a period of at least the preceding 3 years;]

(1)*either* [II.3.4. free from infectious bovine rhinotracheitis/infectious pustular vulvovaginitis and they have never been kept previously in any establishment of a lower health status;]

(1)*or* [II.3.4. not free from infectious bovine rhinotracheitis/infectious pustular vulvovaginitis and the official veterinarian responsible for the establishment of origin has certified that there has been no clinical case of infectious bovine rhinotracheitis/infectious pustular vulvovaginitis during a period of at least the preceding 12 months;]

II.3.5. in which surra (*Trypanosoma evansi*) has not been reported during the last 30 day period prior to collection(1)/ production(1) of the oocytes(1)/ embryos(1), and

(1)*either* [II.3.5.1. surra has not been reported in the establishments during the last 2 years prior to collection(1)/ production(1) of the oocytes(1)/ embryos(1);]

(1)*or* [II.3.5.2. surra has been reported in the establishments during the last 2 years prior to collection(1)/ production(1) of the oocytes(1)/ embryos(1) and following the last outbreak the establishments have remained under movement restrictions until

- the infected animals have been removed from the establishment, and
- the remaining animals on the establishment have been subjected to a test for surra (*Trypanosoma evansi*) with one of the diagnostic methods provided for in Part 3 of Annex I to Commission Delegated Regulation (EU) 2020/688, carried out, with negative results, on samples taken at least 6 months after the infected animals have been removed from the establishment;]

II.4. The oocytes(1)/ embryos(1) described in Part I were obtained from the donor animals which

II.4.1. were not vaccinated against infection with rinderpest virus, infection with Rift Valley fever virus, contagious bovine pleuropneumonia and lumpy skin disease;

II.4.2. remained for a period of at least 6 months prior to the date of collection(1)/ production(1) of the oocytes(1)/ embryos(1) in a country or territory or zone thereof referred to in Part I.;

II.4.3. for a period of at least 30 days prior to the date of collection(1)/ production(1) of the oocytes(1)/ embryos(1) and during the collection period

II.4.3.1. were kept on establishments not situated in a restricted zone established due to the occurrence of foot-and-mouth disease, infection with rinderpest virus, infection with Rift Valley fever virus, contagious bovine pleuropneumonia or lumpy skin disease or of an emerging disease relevant for the bovine animals;

II.4.3.2. were kept on a single establishment where infection with *Brucella abortus, B. melitensis* and *B. suis*, infection with *Mycobacterium tuberculosis* complex (*M.*

bovis, M. caprae and M. tuberculosis), rabies, anthrax, surra *(Trypanosoma evansi),* enzootic bovine leukosis, infectious bovine rhinotracheitis/infectious pustular vulvovaginitis, bovine viral diarrhoea, infection with epizootic haemorrhagic disease virus and infection with bluetongue virus (serotype 1-24) have not been reported;

II.4.3.3. were not in contact with animals from establishments situated in a restricted zone due to the occurrence of diseases referred to in point II.4.3.1. or from establishments which do not meet the conditions referred to in point II.4.3.2.;

II.4.3.4. were not used for natural breeding;

II.4.4. were examined by the team veterinarian or a team member and did not show symptoms or clinical signs of transmissible animal diseases on the day of collection(1)/ production(1) of the oocytes(1)/ embryos(1);

II.4.5. are individually identified as provided for in Article 21(1) of Commission Delegated Regulation (EU) 2020/692;

II.4.6. comply with the following conditions as regards foot-and-mouth disease

II.4.6.1. they come from establishments

- situated in an area where foot-and-mouth disease has not been reported within a 10-km radius centred on the establishment for a period of at least 30 days immediately prior to the date of collection(1)/ production(1) of the oocytes(1)/ embryos(1)
- in which foot-and-mouth disease has not been reported during a period of at least 3 months immediately prior to the date of collection(1)/ production(1) of the oocytes(1)/ embryos(1);

(1)*either* [II.4.6.2. they were not vaccinated against foot-and-mouth disease;]

(1)(4)*or* [II.4.6.2. they were vaccinated against foot-and-mouth disease during the period of 12 months prior to the date of collection of the embryos and

II.4.6.2.1. have not been vaccinated against foot-and-mouth disease within the period of at least 30 days immediately prior to the date of collection of the embryos;

II.4.6.2.2. the semen used for fertilisation was collected from a male donor that complies with the conditions set out in point 1(b) of Chapter I of Part 5 of Annex II to Delegated Regulation (EU) 2020/686 or the semen complies with the conditions set out in point 2 of Chapter I of Part 5 of Annex II to Delegated Regulation (EU) 2020/686;

II.4.6.2.3. prior to freezing, the embryos have been subjected to trypsin washing carried out in accordance with the recommendations of the IETS Manual(5);

II.4.6.2.4. the embryos were stored deep frozen for a period of at least 30 days from the date of collection, and during this period the donor animal has not shown clinical signs of foot-and-mouth disease;]

(1)(6)[II.4.7. comply with at least one of the following conditions as regards infection with bluetongue virus (serotypes 1-24):

(1)*either*[II.4.7.1. they have been kept for a period of at least 60 days prior to and during the collection of the oocytes in a country, territory or zone thereof free from infection with bluetongue virus (serotypes 1-24) and where no case of infection with bluetongue virus (serotypes 1-24) has been confirmed during the last 24 months in the targeted animal population;]

(1)and/or [II.4.7.2.they have been kept in a seasonally disease-free zone, during the seasonally disease-free period, for a period of at least 60 days prior to and during collection of the oocytes, in a country, territory or zone thereof with an approved eradication programme against infection with bluetongue virus (serotype 1-24);]

(1)and/or [II.4.7.3.they have been kept in a seasonally disease-free zone, during the seasonally disease-free period, for a period of at least 60 days prior to and during collection of the oocytes, in a country, territory or zone thereof where the competent authority of the place of origin of the consignment of oocytes(1)/ *in vitro* produced embryos(1) has obtained the prior written consent of the competent authority of the Member State of destination to the conditions for establishment of that seasonally disease-free zone and to accept the consignment of oocytes(1)/ *in vitro* produced embryos(1);]

(1)and/or [II.4.7.4. they have been kept in a vector-protected establishment for a period of at least 60 days prior to and during collection of the oocytes;]

(1)and/or [II.4.7.5. they have been subjected to a serological test to detect antibodies to the bluetongue virus serogroup 1-24, with negative results, between 28 and 60 days from the date of each collection of the oocytes;]

(1)and/or [II.4.7.6. they have been subjected to an agent identification test for bluetongue virus (serotypes 1-24), with negative results, on blood sample taken on the date of collection of the oocytes;]]

(1)(6)[II.4.8. comply with at least one of the following conditions as regards infection with epizootic haemorrhagic disease virus (serotypes 1-7) (EHDV 1-7):

(1)either[II.4.8.1. they have been kept for a period of at least 60 days prior to and during collection of the oocytes in a country, territory or zone thereof where EHDV 1-7 has not been reported for a period of at least the preceding 2 years within a radius of 150 km of the establishment;]

(1)and/or [II.4.8.2.they have been kept in a vector-protected establishment for a period of at least 60 days prior to and during collection of the oocytes;]

(1)and/or [II.4.8.3.were resident in the exporting country in which according to official findings the following serotypes of EHDV exist:…… and have been subjected with negative results in each case to the following tests carried out in an official laboratory:

(1)either [II.4.8.3.1.a serological test to detect antibodies to EHDV 1-7, with negative results, on blood sample taken between 28 and 60 days from the date of the collection of the oocytes;]]

(1)and/or [II.4.8.3.2. an agent identification test for EHDV 1-7, with negative results, on blood sample taken on the date of collection of the oocytes.]]]

(1)(6)[II.4.9. comply with animal health requirements laid down in Chapter III of Part 1 of Annex II to Delegated Regulation (EU) 2020/686;]

II.5. The oocytes(1)/ embryos(1) described in Part I

II.5.1. has been collected, processed and stored in accordance with animal health requirements set out in Part 2(1)/Part 3(1)/Part 4(1)/Part 5(1) and Part 6 of Annex III to Delegated Regulation (EU) 2020/686;

II.5.2. are placed in straws or other packages on which the mark is applied in accordance with requirements provided for in Article 83(a) of Delegated Regulation (EU) 2020/692 and that mark is indicated in Part I;

II.5.3. are transported in a container which:

II.5.3.1. was sealed and numbered prior to the dispatch by the embryo collection or production team under responsibility of the team veterinarian, or by an official veterinarian, and the seal bears the number as indicated in Part 1;

II.5.3.2. has been cleaned and either disinfected or sterilised before use, or is single-use container;

II.5.3.3. has been filled in with the cryogenic agent which not have been previously used for other products;

(1)(7)[II.5.4. are placed in straws or other packages which are securely and hermetically sealed;

II.5.5. are transported in a container where they are separated from each other by physical compartments or by being placed in secondary protective bags.]

(1)(8)[II.6. The *in vivo* derived embryos(1)/ *in vitro* produced embryos(1)/ micromanipulated embryos(1) described in Part I were conceived by artificial insemination using semen coming from a semen collection centre, germinal product processing establishment or germinal product storage centre approved for the collection, processing and/or storage of semen by the competent authority of a third country, territory or zone thereof listed in Annex IX to Implementing Regulation (EU) 2021/404 for semen of bovine animals or by the competent authority of a Member State.]

(1)(9)[II.7. The following antibiotic or mixture of antibiotics(10) has been added to the collection, processing, washing or storage media:……]

Notes

In accordance with the Agreement on the withdrawal of the United Kingdom of Great Britain and Northern Ireland from the European Union and the European Atomic Energy Community, and in particular Article 5(4) of the Protocol on Ireland / Northern Ireland in conjunction with Annex 2 to that Protocol, references to European Union in this certificate include the United Kingdom in respect of Northern Ireland.

This animal health certificate shall be completed according to the notes for the completion of certificates provided for in Chapter 4 of Annex I to Commission Implementing Regulation (EU) 2020/2235.

(1) Delete if not applicable.

(2) Only for a third country, territory or zone thereof with an opening date in accordance with column 9 of the table in Part 1 of Annex II to Implementing Regulation (EU) 2021/404.

(3) Only embryo collection or production teams listed in accordance with Article 233(3) of Regulation (EU) 2016/429 on the Commission website: http://ec.europa.eu/food/animal/semen_ova/bovine/ova_embryos_en.htm.

(4) Option available only for the consignment of *in vivo* derived embryos.

(5) Manual of the International Embryo Transfer Society — A procedural guide and general information for the use of embryo transfer technology emphasising sanitary procedures, published by the International Embryo Transfer Society 1 111 North Dunlap Avenue, Savoy, Illinois 61 874 USA (http://www.iets.org/).

(6) Applicable for the consignment of oocytes and *in vitro* produced embryos.

(7) Applicable for the consignment where in one container oocytes, *in vivo* derived embryos, *in vitro*

produced embryos and micromanipulated embryos of bovine animals are placed and transported.

(8) Does not apply to oocytes.

(9) Mandatory attestation in case antibiotics were added.

(10) Insert the name(s) of the antibiotic(s) added and its(their) concentration.

OV Stamp
Official Veterinarian

Signed .....

Name (BLOCK CAPITALS):……

Date .....

Address